Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28296806 | 0.81 | APLNR (0.42) | APLNRPDCD1CD274CNR1CNR2 | |
| SCHEMBL2016744 | 0.81 | CNR2 (0.46) | APLNRPDCD1CD274CNR1CNR2 | |
| SCHEMBL30215712 | 0.80 | CD274 (0.46) | CD274CNR1CNR2THRATHRB | |
| SCHEMBL29402124 | 0.80 | DHFR (0.48) | — | |
| SCHEMBL16301494 | 0.80 | PDE3B (0.43) | APLNRPDCD1CD274CNR1CNR2 | |
| SCHEMBL120379 | 0.80 | DHFR (0.48) | — | |
| SCHEMBL1552422 | 0.80 | PDCD1 (0.40) | APLNRPDCD1CD274CNR1CNR2 | |
| SCHEMBL6492912 | 0.80 | APLNR (0.47) | APLNRPDCD1CD274ERN1 | |
| SCHEMBL426335 | 0.79 | ALDH1A1 (0.63) | MAOBALDH1A1ERN1 | |
| SCHEMBL1229002 | 0.79 | DHFR (0.53) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | CELLMOSAIC INC (US) | 2021-06-10 | — | — | US | claimed |
| CN-112584871-A | Branched sugar alcohol-based compounds and compositions and methods thereof | 希默赛生物技术公司 | 2021-03-30 | — | — | CN | claimed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | CELLMOSAIC INC (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112584871-A | Branched sugar alcohol-based compounds and compositions and methods thereof | 希默赛生物技术公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20050047976-A1 | Method and apparatus for solid or solution phase reaction under ambient or inert conditions | SENOMYX, INC. | 2005-03-03 | — | — | US | disclosed |
| EP-1499893-A2 | CHEMICALLY INERT MOLECULAR ALKANE OR OXAALKANE-TAGS AND THEIR IDENTIFICATION BY REACTION WITH FLUOROALKANOYL ACIDS | PHARMACOPEIA, INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6310244-B1 | DEMONSTRATES THE ABILITY TO WITHSTAND MANY COMMON REACTION CONDITIONS AND YET IS CLEAVABLE UNDER RELATIVELY MILD CONDITIONS. | PHARMACOPEIA, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010025084-A1 | Photocleavable and acid cleavable linkers for combinatorial chemistry | PHARMACOPEIA, LLC | 2001-09-27 | — | — | US | disclosed |
| US-6175020-B1 | 2-(((ALK)OXY OR AMINO)CARBONYLMETHYL),9-((PROTECTED)AMINOMETHYL)-1-AZASPIRO(4.4)NONANE COMPOUNDS, USEFUL AS TEMPLATE FOR CONSTRUCTING SYNTHETIC RECEPTORS AND AS INTERMEDIATES IN THE SYNTHESIS OF ENZYME INHIBITORS | PHARMACOPEIA, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6093799-A | Universal linker for combinatorial synthesis | PHARMACOPEIA, INC. (US) | 2000-07-25 | — | — | US | disclosed |
| WO-2000005197-A1 | PHOTOCLEAVABLE AND ACID CLEAVABLE LINKERS FOR COMBINATORIAL CHEMISTRY | PHARMACOPEIA, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| US-6008321-A | Universal linker for combinatorial synthesis | PHARMACOPEIA, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999047498-A1 | UNIVERSAL LINKER FOR COMBINATORIAL SYNTHESIS | PHARMACOPEIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999039207-A1 | ACID CLEAVABLE PHENOXYALKYL LINKER FOR COMBINATORIAL SYNTHESIS | PHARMACOPEIA, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | APLNR 316/4885PDCD1 2765/4885CD274 3166/4885 |
| US-20210170037-A1 | BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF | SIGLEC7, CD44, SIGLEC9 | APLNR 2040/4885PDCD1 3008/4885CD274 1183/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | APLNR 316/4885PDCD1 2765/4885CD274 3166/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | APLNR 316/4885PDCD1 2765/4885CD274 3166/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | APLNR 316/4885PDCD1 2765/4885CD274 3166/4885 |
| US-20010025084-A1 | Photocleavable and acid cleavable linkers for combinatorial chemistry | CCNE1, CCNB1, CDK1 | APLNR 3178/4885PDCD1 3669/4885CD274 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.